Partners

We Share a Mutual Goal:
to Make Drugs That Work

Partner with the leaders in predictive transcriptomics to accelerate your drug discovery and development programs.

Your Data, Our AI and Expertise

How We Engage

You have clinical and multi-omic data capable of unlocking key insights in drug discovery and development.

Our mission is to help you drive clinical and scientific decision-making forward by applying advanced computational methods that reveal the answers lying within your data.

Identify Hypothesis

Our joint development teams consider your scientific questions, generate hypotheses, and prioritize opportunities likely to yield the most value

Analyze Results

The most advanced available, proprietary computational methods are employed to analyze, visualize, and document results

Source & Prep Data

We combine your data (patient data, meta data, and RNA-seq) with publicly available data (public samples, literature) for analysis and reanalysis

Deep Analysis

We interpret your results to generate insights/action including preparing evidence for publication and regulatory submissions

Past Projects Include

Preclinical

  • Organoid & cell lines: baselining analysis & multi-omic analysis (post-treated)
  • Tumor: multiple dose combinations; factorial, time course & alternate dosing analysis
  • Cross-model analysis of multi-omic biomarkers predictive of response & resistance
  • Review of biomarker incidence in samples with relevant cancers in public data

Clinical

  • Patient stratification and response prediction
  • Characterize the transcriptomic impact and functional profiling to uncover biological effects
  • Explore biomarkers of response and resistance in each arm and cross arms
  • Explore potential targets in resistance
  • Assist in preparing evidence and analysis for publication and regulatory purposes

Accelerating Knowledge to Benefit Patients

Success Stories

Identifying Novel Gene Targets in ICI-resistant Gastric Cancer

In collaboration with Samsung Medical Center, Ocean Genomics identified 7 novel gene candidates with potential to improve outcomes in ICI-resistant gastric cancer patients. See ASCO 2020 Abstract >

Discovering Responder Predictive Markers in mCRC

In a project with the National Cancer Center Hospital East, Ocean Genomics identified 10 potential predictive markers for response to eribulin in mutant metastatic colorectal cancer patients. See ASCO 2021 Abstract >

Validating a Drug Candidate by Determining Gene-Expression Impact

Ocean Genomics assisted a partner in identifying 22 significant pathways from a list of 4700 differentially expressed genes in response to a promising melanoma candidate.

Furthermore, we demonstrated that the ratio of beneficial to non-beneficial pathway impacts was higher than standard of care, enabling candidate to advance.

Co-Developing Assets with a Strategic Partner Across Leading Cancer Centers

Ocean Genomics’ partnership with Geninus to develop bio-predictive assets leveraged their data sets to develop and commercialize a predictive biomarker for response to immunotherapy in gastric cancer.

Contact Us